CYP2C9, CYP2J2, and soluble epoxide hydrolase (sEH) have been shown to be involved in the formation and metabolism of vasoactive epoxides of the epoxygenase pathway which have been proposed to play a role in the pathogenesis of hypertension and progression of renal failure. We studied the frequency of CYP2C9*8 and *11, sEH R287Q and anR403insertion, and CYP2J2*2-*7 and the newly identified CYP2J2 polymorphisms R49S, L50L, V113M, N124S in 97 AA end-stage renal disease (ESRD) patients and 84 healthy AA to determine whether there is a significant difference in prevalence rates of these polymorphisms. The mean age of the ESRD patients 53.3 ± 12.1 years (mean ± SD) and the healthy AA was 36.8 ± 8.6 years. The ESRD patients and healthy subjects were 43.3% and 40.3% female, respectively. The DNA was isolated from peripheral blood mononuclear cells and then genotyped for the variant alleles using TaqMan-based allelic discrimination assays at the University of Washington in Seattle. The prevalence of the new CYP2J2 variant alleles ranged from 0 to 1.1% in the healthy and ESRD populations except for CYP2J2*7 allele (Table). Additional results for higher frequency alleles are shown in the table below. There was no significant difference in prevalence rates of any of the variant alleles between ESRD and healthy subjects.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.